CH
SRPT icon

Cromwell Holdings’s Sarepta Therapeutics SRPT Stock Holding History

Cromwell Holdings’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$270 Buy
+15
New +$284 ﹤0.01% 1084
2025
Q2 		– Sell
-6
Closed -$383 – 1020
2025
Q1 		$383 Buy
+6
New +$632 ﹤0.01% 778

Other funds holding SRPT

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
GIC
Generali Investments CEE Prague, Czech Republic $2.11B AUM 25.53% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
YCM
Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

Cromwell Holdings's SRPT Position: Q2 2026 in Review

Cromwell Holdings opened a new position in Sarepta Therapeutics (SRPT) in Q2 2026: 15 shares worth $270. The stake represents ﹤0.01% of the portfolio and ranks #1084 among its holdings. This is a return to the name: Cromwell Holdings previously reported a position in SRPT as recently as Q1 2025.

Cromwell Holdings first reported a position in SRPT in Q1 2025 and has held it in 2 quarters since. The position peaked at $383 in Q1 2025. 28 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Cromwell Holdings held 15 shares of Sarepta Therapeutics worth $270 as of Q2 2026.
  • Sarepta Therapeutics was a new Cromwell Holdings position in Q2 2026.
  • Sarepta Therapeutics made up ﹤0.01% of Cromwell Holdings's portfolio in Q2 2026, its #1084 holding.
  • Cromwell Holdings first reported a position in Sarepta Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • Cromwell Holdings's Sarepta Therapeutics position peaked at $383 in Q1 2025.
  • 28 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Cromwell Holdings's 13F filing for Q2 2026, filed 14 Jul 2026.